By Lauren C. JohnsonThe EDSh study is one of the largest studies of its kind in the U.S. The study is the largest clinical trial of its type in the United States.
The researchers from the University of Minnesota and the University at Buffalo and the American Heart Association have conducted the EDShan study, which will be published online in the Annals of Internal Medicine in January.
The study is expected to provide a better understanding of how to help people who have heartburn, said Dr. David G. Zimroth, a Mayo Clinic cardiologist who leads the research.
It will be the first large-scale clinical trial that provides an accurate picture of the effects of EDSham, a treatment approved by the Food and Drug Administration for people with chronic heartburn.
Heartburn is a common and debilitating condition, affecting up to 1.3 million people in the country and more than 200,000 in the developed world.
Heartburn is most often diagnosed in older people, people with a history of cardiovascular disease, and people with preexisting conditions such as high blood pressure and diabetes.
Symptoms of heartburn vary by person.
Some people are able to tolerate it without symptoms.
Others may develop severe symptoms, such as chest pain, fever, or shortness of breath.
The condition can also cause breathing difficulties, coughing or short-term memory loss.
Heartbreak can be life-threatening.
People can develop chest pain if they have a heart attack or if they inhale too much CO2 or smoke.
People with heartburn also may have a different type of infection called acute myocarditis, which is caused by viruses.
People who have chronic heart disease can have heart attacks that are difficult to manage, and the condition can lead to death.
Heart attacks occur more frequently in people with the most advanced or chronic conditions, such a high blood-pressure, high cholesterol, or diabetes.
The EDAH study is focused on a treatment called EDSheer, which was approved in 2009 and is a non-surgical alternative to surgery.
EDSHEer involves using a special electrode, which can be placed on the inside of the left ventricle and implanted under the skin.
People with heart problems can be given the EDAh treatment as a last resort.
Patients with heart disease who are able and willing to take the EDFh treatment will be evaluated at the Mayo Clinic, according to the Mayo Health Network.
The Mayo study was supported by the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, the Robert Wood Johnson Foundation, the Office of Naval Research, the John S. and James L. Knight Foundation, and others.
Follow Lauren on Twitter @LyleCJohnson, and Lauren on Facebook at Lauren Johnson.